Isomorphic Labs Raises $2.1B to Scale AI Drug Discovery

Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, announced Wednesday it has raised $2.1 billion in its latest funding round led by Thrive Capital. Existing investors Google Ventures and Alphabet also participated, alongside new backers MGX, Temasek, and CapitalG.

CEO Demis Hassabis said the capital will be used to scale the company's drug design engine, aiming to "solve all diseases." Isomorphic was founded in 2021 as a spin-off from Google DeepMind, known for its AlphaFold AI program that predicts protein structures, helping scientists design drugs more effectively.

The company now expects its first clinical trials by the end of 2026, a delay from the earlier target of 2025. Isomorphic raised $600 million in its first funding round last year.